Cargando…

Multi-omics and temporal dynamics profiling reveal disruption of central metabolism in Helicobacter pylori on bismuth treatment

Integration of multi-omics enables uncovering cellular responses to stimuli or the mechanism of action of a drug at a system level. Bismuth drugs have long been used for the treatment of Helicobacter pylori infection and their antimicrobial activity was attributed to dysfunction of multiple proteins...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Bingjie, Zhang, Zhen, Xie, Yanxuan, Hu, Xuqiao, Wang, Haibo, Xia, Wei, Wang, Yulan, Li, Hongyan, Wang, Yuchuan, Sun, Hongzhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Royal Society of Chemistry 2018
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223348/ https://www.ncbi.nlm.nih.gov/pubmed/30510674 http://dx.doi.org/10.1039/c8sc01668b

Ejemplares similares

Integrative approach for the analysis of the proteome-wide response to bismuth drugs in Helicobacter pylori
por: Wang, Yuchuan, et al.
Publicado: (2017)

Combination of gallium(iii) with acetate for combating antibiotic resistant Pseudomonas aeruginosa
por: Wang, Yuchuan, et al.
Publicado: (2019)

Suppression of Helicobacter pylori Infection With Bismuth Subsalicylate: Was It the Bismuth or the Salicylate?
por: Kunin, Calvin M
Publicado: (2022)

Bismuth: Environmental Pollution and Health Effects
por: Wang, Runming, et al.
Publicado: (2019)

Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020)

Recent advances in bioinorganic chemistry of bismuth
por: Li, Hongyan, et al.
Publicado: (2012)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Successful Suppression of Drug-Resistant Helicobacter pylori Infection With Bismuth Subsalicylate
por: Geng, Calvin, et al.
Publicado: (2022)

Bismuth Porphyrin Antagonizes Cisplatin-Induced Nephrotoxicity via Unexpected Metallothionein-Independent Mechanisms
por: Wang, Runming, et al.
Publicado: (2020)

Deciphering molecular mechanism of silver by integrated omic approaches enables enhancing its antimicrobial efficacy in E. coli
por: Wang, Haibo, et al.
Publicado: (2019)

Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori
por: Wang, Junxian, et al.
Publicado: (2021)

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
por: Jheng, Guang-Hong, et al.
Publicado: (2015)

Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
por: Niu, Zhan-Yue, et al.
Publicado: (2021)

Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
por: Zhang, Lingyun, et al.
Publicado: (2019)

Multifaceted SlyD from Helicobacter pylori: implication in [NiFe] hydrogenase maturation
por: Cheng, Tianfan, et al.
Publicado: (2011)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

Corrigendum to “Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori”
por: Zhang, Lingyun, et al.
Publicado: (2021)

Effect of licorice versus bismuth on eradication of Helicobacter pylori in patients with peptic ulcer disease
por: Momeni, Ali, et al.
Publicado: (2014)

Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017)

The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020)

Rescue effects of Lactobacillus-containing bismuth regimens after Helicobacter pylori treatment failure
por: Karbalaei, M., et al.
Publicado: (2021)

"Targeted disruption of the epithelial-barrier by Helicobacter pylori"
por: Wroblewski, Lydia E, et al.
Publicado: (2011)

Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
por: Wu, Meng-Chieh, et al.
Publicado: (2017)

Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori
por: Li, Lei, et al.
Publicado: (2018)

Short-Duration Furazolidone Therapy in Combination with Amoxicillin, Bismuth Subcitrate, and Omeprazole for Eradication of Helicobacter pylori
por: Hasan, Salman R., et al.
Publicado: (2010)

Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia
por: Alsohaibani, Fahad, et al.
Publicado: (2020)

The efficacy and safety of furazolidone-bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotic supplementation
por: Noorbakhsh, Nafeh, et al.
Publicado: (2022)

Bacterial Membrane Vesicles as a Novel Strategy for Extrusion of Antimicrobial Bismuth Drug in Helicobacter pylori
por: Kumar, Sumith, et al.
Publicado: (2022)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency
por: Lee, Moon Won, et al.
Publicado: (2022)

Relationship between Helicobacter pylori infection and osteoporosis: a systematic review and meta-analysis
por: Wang, Taiwu, et al.
Publicado: (2019)

Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey
por: Alkim, Huseyin, et al.
Publicado: (2011)

Efficacy of Clarithromycin Containing Bismuth–Based Regimen as a Second-Line Therapy in Helicobacter Pylori Eradication
por: Mokhtare, Marjan, et al.
Publicado: (2015)

Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin
por: Song, Zhiqiang, et al.
Publicado: (2019)

Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
por: Kim, Jeemyoung, et al.
Publicado: (2022)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy
por: Sun, Yingchao, et al.
Publicado: (2022)

Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
por: Kim, Ji Yoon, et al.
Publicado: (2023)

The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after Helicobacter pylori Eradication: A Randomized Controlled Trial
por: Wu, Dingkun, et al.
Publicado: (2022)

The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial
por: Cao, Yaping, et al.
Publicado: (2021)

Fucoidans Disrupt Adherence of Helicobacter pylori to AGS Cells In Vitro
por: Chua, Eng-Guan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gmchueift1cak49nqk2268ffhk